Rituximab for idiopathic membranous nephropathy

Giuseppe Remuzzi, Carlos Chiurchiu, Mauro Abbate, Verusca Brusegan, Mario Bontempelli, Piero Ruggenenti

Research output: Contribution to journalArticlepeer-review

Abstract

Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m2) - the monoclonal antibody to B-cell antigen CD20 - in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p

Original languageEnglish
Pages (from-to)923-924
Number of pages2
JournalLancet
Volume360
Issue number9337
DOIs
Publication statusPublished - Sep 21 2002

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Rituximab for idiopathic membranous nephropathy'. Together they form a unique fingerprint.

Cite this